Developer docs
API playgroundTry for free, no card

Search company profiles

Asensus Surgical

Full company profile

uuid0000cr9

Namestring
Asensus Surgical
Legal namestring
Asensus Surgical US, Inc.
Websiteurl
asensus.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Asensus Surgical was a U.S.-based medical device company headquartered in Durham, North Carolina, that developed and commercialized a digital laparoscopy platform for robotic-assisted minimally invasive surgery. Its core offering, the Senhance Surgical System, was an FDA- and CE-cleared digital laparoscopy platform featuring an open ergonomic console, reusable 3mm and 5mm instruments, Tobii-supplied eye-tracking camera control, and an integrated Intelligent Surgical Unit (ISU) that applied computer vision to surgical video in real time. The company positioned itself around what it termed Performance-Guided Surgery, layering AI-derived anatomical recognition, digital measurement, tagging, and semi-autonomous haptic "no fly zone" safety features onto a robot platform — and held what it described as the first FDA and CE approval for real-time Augmented Intelligence use intraoperatively.

The business model combined capital equipment sales of the Senhance console to hospitals and surgical centers with recurring revenue from service and support contracts and consumable instrument sales. GTM was enterprise-direct, with a small international sales and physician-partner team targeting surgeons and hospital administrators across North America, Europe, and Japan. The company supplemented its commercial effort with clinical publications, white papers, and content marketing aimed at top- and mid-funnel awareness, while a separate Luna next-generation robotic system (developed in partnership with GlobalLogic and benefiting from an NVIDIA collaboration on AI optimization) targeted a broader AI-native architecture. From 2018 onward the ISU was the principal technical differentiator; the company was acquired by KARL STORZ in August 2024 for approximately $35 million and has since been fully integrated, with the Senhance and Luna hardware platforms discontinued in favor of a connected, software-enabled operating room strategy pursued by the parent.

Short descriptiontext

Asensus Surgical, now a wholly-owned subsidiary of KARL STORZ, developed the FDA/CE-cleared Senhance digital laparoscopy platform with the Intelligent Surgical Unit for real-time intraoperative Augmented Intelligence, serving surgeons and hospital administrators globally.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
robotic surgical systems, digital laparoscopy platform, augmented intelligence surgery, minimally invasive robotics, surgical instrument technology
Industry3 codes
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAE
Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLACAGAJ
Surgical, Perioperative & ERAS Pathway Tools
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Robotic Surgical Systems
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Surgical Robotic Systems
TypeHardware Sales
Description

Sale of Senhance Surgical System hardware to hospitals and surgical centers for use in operating rooms.

asensus.com
2Service and Support Contracts
TypeSubscription Recurring
Description

Ongoing service, training, and support services for installed base of Senhance systems.

asensus.com
3Surgical Instruments
TypeHardware Sales
Description

Sale of compatible, reusable 3mm and 5mm instruments for use with the Senhance system.

asensus.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Senhance Surgical System
Description

The first digital laparoscopy platform with Augmented Intelligence capabilities for general laparoscopic, gynecological, and urological surgery procedures.

asensus.com
+3 more records
Core offering1 text field

Asensus Surgical develops and sells the Senhance Surgical System, a digital laparoscopy platform for robotic-assisted minimally invasive abdominal surgery. The platform integrates the Intelligent Surgical Unit (ISU), the first FDA and CE approved real-time Augmented Intelligence system for intraoperative use, providing computer-vision insights, digital tagging, critical anatomy identification, and haptic-feedback safety features. Supporting offerings include reusable 3mm/5mm instruments, Senhance Connect for global tele-mentoring, and Senhance Simulation for surgeon training.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduced mental burden for surgeons through digital assistant features
+3 more records
Product overview1 text field

Asensus Surgical offers a digital laparoscopy platform built around the Senhance Surgical System as its core product. The platform integrates an Intelligent Surgical Unit (ISU) providing real-time Augmented Intelligence, supplemented by Senhance Connect for global teleconsultation capabilities and Senhance Simulation for training. Additional modules include the augmentOR Portal for surgical analytics. The company is developing the Luna next-generation robotic system incorporating AI, computer vision, and machine learning. The ecosystem is unified by the Performance-Guided Surgery approach, which layers digital intelligence onto surgical robotics to enable consistently superior outcomes.

Product and service7 records
1Senhance Surgical System
CategoryRobotic Surgical Platform
Description

The first and only FDA and CE approved digital laparoscopy platform for robotic-assisted minimally invasive surgery, providing accurate control of laparoscopic instruments with an open ergonomic design, eye tracker cameras, and 3mm and 5mm compatible reusable instruments for general, gynecological, and urological procedures in adult and pediatric patients.

2Intelligent Surgical Unit (ISU)
CategorySurgical Intelligence Software Module
Description

The world's first real-time Augmented Intelligence platform for intraoperative use, providing surgeons with digital insights and decision support during procedures through computer vision, pattern recognition, and real-time data analytics, with FDA and CE approval.

3Senhance Connect
CategoryRemote Collaboration Software Module
Description

A telemedicine module enabling real-time access to a second clinical opinion in the Operating Room, allowing healthcare professionals globally to support and mentor one another 24/7 during surgical procedures, regardless of geography.

4Senhance Simulation
CategorySurgical Training Platform
Description

Simulation training platform for the Senhance Surgical System, enabling surgeons to practice procedures and familiarize themselves with the technology before clinical use.

5Luna Robotic Surgical System
CategoryNext-Generation Robotic Surgery System
Description

Next-generation robotic surgery system incorporating AI, computer vision, and machine learning capabilities, being developed with engineering partnership; targeted for advanced surgical robotics with embedded AI architecture.

6augmentOR Portal
CategorySurgical Analytics Portal
Description

A portal providing surgeons with surgical insights and performance data, empowering them with analytical tools to review and improve surgical outcomes.

7Digital Solutions (Performance-Guided Surgery)
CategoryDigital Surgery Software Suite
Description

Suite of digital tools delivering actionable insights during procedures to enhance surgical decision-making and reduce variability, unified under the Performance-Guided Surgery approach.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-17
Description

Long-term engineering partnership to develop Luna, Asensus's next-generation robotic surgery system, incorporating AI, computer vision, and machine learning capabilities. The collaboration includes establishing a new development lab in Kraków, Poland to handle verification and validation for medical devices using GlobalLogic's DeviceSure test accelerator.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-30
Description

Collaboration with NVIDIA to optimize surgical AI capabilities. NVIDIA has struck deals with healthcare domain experts to advance AI solutions, with Asensus cited as an example of pairing tech experts with domain specialists for medical AI development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Maker of the da Vinci Surgical System, the dominant soft-tissue robotic surgery platform. Directly comparable to Asensus in target customers (hospitals and surgeons) and minimally invasive surgery use cases, with vastly larger installed base.

TypeEmerging player
Description

Swiss developer of the Dexter robotic surgery system focused on general, gynecological and urological laparoscopy. Directly comparable as a smaller laparoscopic robotic competitor with similar indications and customer base.

TypeBroad incumbent
Description

Diversified medtech incumbent that launched the Hugo robotic-assisted surgery platform competing with Senhance in laparoscopic/soft-tissue robotics. Comparable as a broad incumbent expanding into Asensus's category with much larger balance sheet and distribution.

TypeBroad incumbent
Description

Operates the Mako robotic-assisted surgery platform (orthopedics) and a broad surgical/endoscopy portfolio. Comparable as a diversified incumbent competing for hospital capital budgets and OR integration slots.

TypeDirect peer
Description

Developer of the Versius surgical robotic system, a modular laparoscopic robot aimed at general surgery, gynecology and urology. Closely comparable to Senhance in indication, customer and portable-form-factor positioning.

TypeOthers
Description

Parent company of Asensus and global leader in endoscopy and OR visualization. Relevant peer as the acquirer integrating Asensus IP into its connected-OR roadmap and as a broader OR equipment peer serving the same hospital buyers.

TypeBroad incumbent
Description

Markets the CORI handheld robotics platform for orthopedics and a broader surgical portfolio. Comparable as a medtech incumbent with surgical robotics ambitions targeting hospital customers.

TypeEmerging player
Description

Early-stage developer of a next-generation robotic surgery system with combined virtual reality and proprietary instrumentation, overlapping Asensus's surgical robotics R&D and minimally invasive surgery target use cases.

TypeBroad incumbent
Description

Develops the Ottava robotic surgery system within its Ethicon franchise. A broad incumbent in surgical instruments and OR products that overlaps Asensus's hospital/surgeon customer base and OR-integration roadmap.

TypeEmerging player
Description

Developer of minimally invasive surgical robotics technology originating from Memic Innovation. Comparable as an emerging soft-tissue robotic player with overlapping indication set and hospital customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Asensus Surgical

Robotic Surgical Systemsasensus.com

Asensus Surgical, now a wholly-owned subsidiary of KARL STORZ, developed the FDA/CE-cleared Senhance digital laparoscopy platform with the Intelligent Surgical Unit for real-time intraoperative Augmented Intelligence, serving surgeons and hospital administrators globally.

What Asensus Surgical does

Asensus Surgical was a U.S.-based medical device company headquartered in Durham, North Carolina, that developed and commercialized a digital laparoscopy platform for robotic-assisted minimally invasive surgery. Its core offering, the Senhance Surgical System, was an FDA- and CE-cleared digital laparoscopy platform featuring an open ergonomic console, reusable 3mm and 5mm instruments, Tobii-supplied eye-tracking camera control, and an integrated Intelligent Surgical Unit (ISU) that applied computer vision to surgical video in real time. The company positioned itself around what it termed Performance-Guided Surgery, layering AI-derived anatomical recognition, digital measurement, tagging, and semi-autonomous haptic "no fly zone" safety features onto a robot platform — and held what it described as the first FDA and CE approval for real-time Augmented Intelligence use intraoperatively.

The business model combined capital equipment sales of the Senhance console to hospitals and surgical centers with recurring revenue from service and support contracts and consumable instrument sales. GTM was enterprise-direct, with a small international sales and physician-partner team targeting surgeons and hospital administrators across North America, Europe, and Japan. The company supplemented its commercial effort with clinical publications, white papers, and content marketing aimed at top- and mid-funnel awareness, while a separate Luna next-generation robotic system (developed in partnership with GlobalLogic and benefiting from an NVIDIA collaboration on AI optimization) targeted a broader AI-native architecture. From 2018 onward the ISU was the principal technical differentiator; the company was acquired by KARL STORZ in August 2024 for approximately $35 million and has since been fully integrated, with the Senhance and Luna hardware platforms discontinued in favor of a connected, software-enabled operating room strategy pursued by the parent.

Asensus Surgical firmographics

Firmographics
Name
Asensus Surgical
Legal name
Asensus Surgical US, Inc.
Website
https://asensus.com
Company type
Private
Founded year
2014
Operating status
Acquired
Headcount range
101–250 employees
Short description
Asensus Surgical, now a wholly-owned subsidiary of KARL STORZ, developed the FDA/CE-cleared Senhance digital laparoscopy platform with the Intelligent Surgical Unit for real-time intraoperative Augmented Intelligence, serving surgeons and hospital administrators globally.
Ownership category
akta.pro rank

Asensus Surgical industry classification

Industry
Product category
Robotic Surgical Systems
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAE
Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLACAGAJ
Surgical, Perioperative & ERAS Pathway Tools
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Robotic surgical systems
  • Digital laparoscopy platform
  • Augmented intelligence surgery
  • Minimally invasive robotics
  • Surgical instrument technology

Where Asensus Surgical is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Asensus Surgical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Surgical Robotic Systems: Sale of Senhance Surgical System hardware to hospitals and surgical centers for use in operating rooms.
  2. Service and Support Contracts: Ongoing service, training, and support services for installed base of Senhance systems.
  3. Surgical Instruments: Sale of compatible, reusable 3mm and 5mm instruments for use with the Senhance system.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Asensus Surgical product offering

Product offering

Core offering

Asensus Surgical develops and sells the Senhance Surgical System, a digital laparoscopy platform for robotic-assisted minimally invasive abdominal surgery. The platform integrates the Intelligent Surgical Unit (ISU), the first FDA and CE approved real-time Augmented Intelligence system for intraoperative use, providing computer-vision insights, digital tagging, critical anatomy identification, and haptic-feedback safety features. Supporting offerings include reusable 3mm/5mm instruments, Senhance Connect for global tele-mentoring, and Senhance Simulation for surgeon training.

Product overview

Asensus Surgical offers a digital laparoscopy platform built around the Senhance Surgical System as its core product. The platform integrates an Intelligent Surgical Unit (ISU) providing real-time Augmented Intelligence, supplemented by Senhance Connect for global teleconsultation capabilities and Senhance Simulation for training. Additional modules include the augmentOR Portal for surgical analytics. The company is developing the Luna next-generation robotic system incorporating AI, computer vision, and machine learning. The ecosystem is unified by the Performance-Guided Surgery approach, which layers digital intelligence onto surgical robotics to enable consistently superior outcomes.

Differentiator

Problem solved

Functional benefit

Brands

  • Senhance Surgical System: The first digital laparoscopy platform with Augmented Intelligence capabilities for general laparoscopic, gynecological, and urological surgery procedures.
  • Senhance Connect
  • Intelligent Surgical Unit (ISU)
  • LUNA Robotic Surgical System

Products and services

  • Senhance Surgical System The first and only FDA and CE approved digital laparoscopy platform for robotic-assisted minimally invasive surgery, providing accurate control of laparoscopic instruments with an open ergonomic design, eye tracker cameras, and 3mm and 5mm compatible reusable instruments for general, gynecological, and urological procedures in adult and pediatric patients.
  • Intelligent Surgical Unit (ISU) The world's first real-time Augmented Intelligence platform for intraoperative use, providing surgeons with digital insights and decision support during procedures through computer vision, pattern recognition, and real-time data analytics, with FDA and CE approval.
  • Senhance Connect A telemedicine module enabling real-time access to a second clinical opinion in the Operating Room, allowing healthcare professionals globally to support and mentor one another 24/7 during surgical procedures, regardless of geography.
  • Senhance Simulation Simulation training platform for the Senhance Surgical System, enabling surgeons to practice procedures and familiarize themselves with the technology before clinical use.
  • Luna Robotic Surgical System Next-generation robotic surgery system incorporating AI, computer vision, and machine learning capabilities, being developed with engineering partnership; targeted for advanced surgical robotics with embedded AI architecture.
  • augmentOR Portal A portal providing surgeons with surgical insights and performance data, empowering them with analytical tools to review and improve surgical outcomes.
  • Digital Solutions (Performance-Guided Surgery) Suite of digital tools delivering actionable insights during procedures to enhance surgical decision-making and reduce variability, unified under the Performance-Guided Surgery approach.

Quantifiable outcome

  • Reduced mental burden for surgeons through digital assistant features
  • +3 more outcomes

Companies that use Asensus Surgical

Customer profile

Segments4 records

Ideal customer profiles1 record

Asensus Surgical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature6 records

Asensus Surgical partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • GlobalLogiccoreStrategic or Co-development Partner · 17 October 2025Long-term engineering partnership to develop Luna, Asensus's next-generation robotic surgery system, incorporating AI, computer vision, and machine learning capabilities. The collaboration includes establishing a new development lab in Kraków, Poland to handle verification and validation for medical devices using GlobalLogic's DeviceSure test accelerator.
  • NVIDIAcoreStrategic or Co-development Partner · 30 September 2024Collaboration with NVIDIA to optimize surgical AI capabilities. NVIDIA has struck deals with healthcare domain experts to advance AI solutions, with Asensus cited as an example of pairing tech experts with domain specialists for medical AI development.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Asensus Surgical competitors and assessment

Company assessment

Direct peers

  • Intuitive Surgical: Maker of the da Vinci Surgical System, the dominant soft-tissue robotic surgery platform. Directly comparable to Asensus in target customers (hospitals and surgeons) and minimally invasive surgery use cases, with vastly larger installed base.
  • CMR Surgical: Developer of the Versius surgical robotic system, a modular laparoscopic robot aimed at general surgery, gynecology and urology. Closely comparable to Senhance in indication, customer and portable-form-factor positioning.

Emerging players

  • Distalmotion: Swiss developer of the Dexter robotic surgery system focused on general, gynecological and urological laparoscopy. Directly comparable as a smaller laparoscopic robotic competitor with similar indications and customer base.
  • Vicarious Surgical: Early-stage developer of a next-generation robotic surgery system with combined virtual reality and proprietary instrumentation, overlapping Asensus's surgical robotics R&D and minimally invasive surgery target use cases.
  • Momentis Surgical: Developer of minimally invasive surgical robotics technology originating from Memic Innovation. Comparable as an emerging soft-tissue robotic player with overlapping indication set and hospital customers.

Broad incumbents

  • Medtronic: Diversified medtech incumbent that launched the Hugo robotic-assisted surgery platform competing with Senhance in laparoscopic/soft-tissue robotics. Comparable as a broad incumbent expanding into Asensus's category with much larger balance sheet and distribution.
  • Stryker: Operates the Mako robotic-assisted surgery platform (orthopedics) and a broad surgical/endoscopy portfolio. Comparable as a diversified incumbent competing for hospital capital budgets and OR integration slots.
  • Smith+Nephew: Markets the CORI handheld robotics platform for orthopedics and a broader surgical portfolio. Comparable as a medtech incumbent with surgical robotics ambitions targeting hospital customers.
  • Johnson & Johnson MedTech: Develops the Ottava robotic surgery system within its Ethicon franchise. A broad incumbent in surgical instruments and OR products that overlaps Asensus's hospital/surgeon customer base and OR-integration roadmap.

Others

  • KARL STORZ SE & Co. KG: Parent company of Asensus and global leader in endoscopy and OR visualization. Relevant peer as the acquirer integrating Asensus IP into its connected-OR roadmap and as a broader OR equipment peer serving the same hospital buyers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Asensus Surgical social profiles

Digital presence

Asensus Surgical compliance and trust

Trust signal

Compliance1 record

Asensus Surgical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Asensus Surgical leadership team

Management profile

Number of profiles

Profiles8 records

Asensus Surgical funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Asensus Surgical M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asensus Surgical

What does Asensus Surgical do?

Asensus Surgical develops and sells the Senhance Surgical System, a digital laparoscopy platform for robotic-assisted minimally invasive abdominal surgery. The platform integrates the Intelligent Surgical Unit (ISU), the first FDA and CE approved real-time Augmented Intelligence system for intraoperative use, providing computer-vision insights, digital tagging, critical anatomy identification, and haptic-feedback safety features. Supporting offerings include reusable 3mm/5mm instruments, Senhance Connect for global tele-mentoring, and Senhance Simulation for surgeon training.

Is Asensus Surgical a public or private company?

Asensus Surgical is a private company. It is classified as corporate owned and is currently acquired.

When was Asensus Surgical founded?

Asensus Surgical was founded in 2014. It employs 101 to 250 people.

Where is Asensus Surgical based?

Asensus Surgical is headquartered in Morrisville, United States, in the North America region.

How does Asensus Surgical make money?

Three revenue lines are on record. Surgical Robotic Systems are the primary driver. The others are service and Support Contracts and surgical Instruments.

Who are Asensus Surgical's main competitors?

Direct peers on record are Intuitive Surgical and CMR Surgical. Emerging players are Distalmotion, Vicarious Surgical and Momentis Surgical. Broad incumbents are Medtronic, Stryker, Smith+Nephew and Johnson & Johnson MedTech. KARL STORZ SE & Co. KG is listed as an others.

Does Asensus Surgical have an API?

No public API is recorded for Asensus Surgical.

What industry is Asensus Surgical in?

Asensus Surgical's product category is Robotic Surgical Systems. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAE, Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ABC11 Raleigh-DurhamMorrisville robotic surgery company to lay off 108 workersAsensus Surgical announced it will lay off 108 workers at its Morrisville, North Carolina facility over a six-month period beginning August 15. The company attributed the reduction in force to organizational realignment and current business conditions. The facility is expected to remain open following these layoffs.openPR.comMinimally Invasive Thoracic Surgery Market Overview, Current Trends, and Key Player AnalysisThe minimally invasive thoracic surgery market is projected to reach $6.46 billion by 2030, growing at a compound annual growth rate of 8.1%, driven by advancements in robotic platforms, AI-guided surgical planning, and increased demand for less invasive procedures. In a notable transaction, KARL STORZ Endoscopy America Inc. acquired Asensus Surgical Inc. for $0.35 per share in cash in August 2024, aimed at strengthening KARL STORZ's capabilities in digital and robotic-assisted surgical platforms. The market report identifies key trends including the expansion of video-assisted thoracoscopic surgery, advanced visualization technologies, and precision energy devices.openPR.comKey Factors and Emerging Trends Shaping the Gynecology Robotic Surgery Market LandscapeThe Business Research Company published a market report on the gynecology robotic surgery sector, forecasting it will reach $5.05 billion by 2030 at a 9.2% CAGR, driven by next-generation robotic platform adoption and AI-assisted surgical planning. In August 2024, German endoscopy manufacturer KARL STORZ SE & Co. KG acquired US-based Asensus Surgical, Inc. to integrate its digital laparoscopic platform into operating rooms globally.EIN PresswireMerit Awards Announces Winners of the 2026 Marketing & Communications AwardsMerit Awards announced the 2026 Marketing & Communications winners on April 13, 2026, honoring organizations for creativity and measurable impact. Winners include Pac/West Strategies, Hyundai Motor America, and FLOLIVE in communications, and Holocaust Museum Boston, SVM PR, and AviaGames in marketing.openPR.comSurgical Microscopes Market Overview, Key Trends, and Major Player AnalysisThe surgical microscopes market is projected to reach $2.99 billion by 2030, growing at a compound annual growth rate of 14.4%, driven by advancements in visualization technology and increasing adoption across neurosurgery, ophthalmology, and spine surgeries. In August 2024, Germany-based KARL STORZ acquired US-based Asensus Surgical to strengthen its digital surgery ecosystem with performance-guided instrumentation and digital operating room tools. In September 2024, Carl Zeiss Meditec AG launched the KINEVO 900 S Robotic Visualization System featuring 4K 3D imaging and voice-controlled cobotic positioning capabilities.openPR.comKey Factors and Emerging Trends Shaping the Surgical Robot Accessories Market LandscapeThe surgical robot accessories market is projected to reach $10.55 billion by 2030, growing at a 13.2% CAGR, driven by increasing adoption of next-generation surgical robots and AI-enabled tools. In August 2024, German medical technology firm KARL STORZ Group acquired US-based Asensus Surgical Inc. for $0.35 per share in cash, representing a 67% premium, to expand its robotic surgery portfolio with Asensus's Intelligent Surgical Unit and LUNA robotic surgical system. Additionally, in April 2024, US-based MMI Inc. received FDA approval for its Symani Surgical System, the only FDA-cleared robotic system in the US dedicated to reconstructive microsurgery.openPR.comAnalysis of Key Market Segments Influencing the Reusable Laparoscopic Instruments MarketThe reusable laparoscopic instruments market is projected to grow to $4.69 billion by 2030, driven by increasing adoption of minimally invasive procedures and demand for cost-effective surgical solutions. In August 2024, KARL STORZ SE & Co. KG, a German endoscopy company, acquired Asensus Surgical Inc. to enhance its capabilities in robotic and digital surgery and support the development of Asensus' next-generation LUNA robotic platform. The market analysis also identifies key industry players and provides detailed segmentation by product type, material, distribution channel, and application.openPR.comCompetitive Landscape: Leading Companies and New Entrants in the Single Port Surgical Platforms MarketThe single port surgical platforms market is projected to reach $2.92 billion by 2030, growing at a 13.5% CAGR, driven by technological advancements in robotic surgery, patient preference for minimally invasive procedures, and integration of AI and imaging technologies. In August 2024, Germany-based Karl Storz SE & Co. KG acquired US-based Asensus Surgical Inc. to strengthen its digital and robotic surgery capabilities, incorporating Asensus's single-port surgical platform technologies. In May 2025, US-based Intuitive Surgical Inc. received FDA approval for its da Vinci Single Port system, designed for transanal local excision and resection procedures through a single 1-inch incision.openPR.comRigid Endoscope Market Overview, Key Trends, and Top Company AnalysisThe rigid endoscope market is projected to reach $7.86 billion by 2030, growing at a CAGR of 8.6%, driven by technological advancements, rising demand for minimally invasive surgeries, and increased focus on patient safety and infection control. In August 2024, Germany-based Karl Storz SE & Co. KG acquired US-based Asensus Surgical for approximately $35 million to strengthen its robotic surgery and digital surgery capabilities. In September 2025, Olympus Corporation of the Americas introduced the VISERA S OTV-S500 imaging platform designed to improve visualization across ENT and urological examinations.openPR.comAbdominal Surgical Robot Market Growth Accelerates as Healthcare Sector Embraces Precision Surgery Solutions - SRIStrategic Revenue Insights Inc. published a market report in April 2026 finding that the global Abdominal Surgical Robot Market is experiencing strong momentum as healthcare systems increasingly adopt advanced robotic technologies for enhanced surgical precision, reduced recovery times, and improved clinical outcomes. The report identifies key players including Intuitive Surgical Inc., Medtronic plc, Stryker Corporation, Johnson and Johnson, Smith and Nephew plc, Zimmer Biomet Holdings Inc., Asensus Surgical Inc., CMR Surgical Ltd., TransEnterix Inc., and Verb Surgical Inc., with North America currently dominating the market while the Asia Pacific region is expected to witness the fastest growth.